PMID- 32725755
OWN - NLM
STAT- MEDLINE
DCOM- 20210720
LR  - 20210720
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 9
IP  - 18
DP  - 2020 Sep
TI  - Patient and caregiver benefit-risk preferences for nonmetastatic 
      castration-resistant prostate cancer treatment.
PG  - 6586-6596
LID - 10.1002/cam4.3321 [doi]
AB  - BACKGROUND: Recently approved second-generation androgen receptor inhibitors 
      (SGARIs) for non-metastatic castration-resistant prostate cancer (nmCRPC) have 
      similar efficacy but differ in safety profiles. We used a discrete choice 
      experiment (DCE) to examine how nmCRPC patients and caregivers perceive the 
      benefits versus risks of these new treatments. METHODS: An online DCE survey with 
      14 treatment choice questions was administered to nmCRPC patients and caregivers. 
      Each choice question compared two hypothetical medication profiles varying in 
      terms of 5 safety attributes (risk or severity of adverse events [AEs]: fatigue, 
      skin rash, cognitive problems, serious fall, and serious fracture) and two 
      efficacy attributes (duration of overall survival [OS] and time to pain 
      progression). Random parameters logit models were used to estimate each 
      attribute's relative importance. We also estimated the amounts of OS that 
      respondents were willing to forego for a reduction in AEs. RESULTS: In total, 143 
      nmCRPC patients and 149 caregivers viewed the AEs in following order of 
      importance (most to least): serious fracture, serious fall, cognitive problems, 
      fatigue, and skin rash. On average, patients were willing to trade 5.8 and 
      4.0 months of OS to reduce the risk of serious fracture and fall, respectively, 
      from 3% to 0%; caregivers were willing to trade 6.6 and 5.4 months of OS. 
      CONCLUSIONS: nmCRPC patients and caregivers preferred treatments with lower AE 
      burdens and were willing to forego OS to reduce the risk and severity of AEs. Our 
      results highlight the importance of carefully balancing risks and benefits when 
      selecting treatments in this relatively asymptomatic population.
CI  - (c) 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Srinivas, Sandy
AU  - Srinivas S
AD  - Stanford University Medical Center, Palo Alto, CA, USA.
FAU - Mohamed, Ateesha F
AU  - Mohamed AF
AD  - Bayer U.S. LLC, Whippany, NJ, USA.
FAU - Appukkuttan, Sreevalsa
AU  - Appukkuttan S
AD  - Bayer U.S. LLC, Whippany, NJ, USA.
FAU - Botteman, Marc
AU  - Botteman M
AUID- ORCID: 0000-0003-2808-7163
AD  - Pharmerit International, LP, Bethesda, MD, USA.
FAU - Ng, Xinyi
AU  - Ng X
AUID- ORCID: 0000-0002-0736-8276
AD  - Pharmerit International, LP, Bethesda, MD, USA.
FAU - Joshi, Namita
AU  - Joshi N
AUID- ORCID: 0000-0001-5577-2890
AD  - Pharmerit International, LP, Bethesda, MD, USA.
FAU - Tsai, Jui-Hua
AU  - Tsai JH
AD  - Pharmerit International, LP, Bethesda, MD, USA.
FAU - Fang, Jarjieh
AU  - Fang J
AD  - Pharmerit International, LP, Bethesda, MD, USA.
FAU - Waldeck, A Reginald
AU  - Waldeck AR
AD  - Bayer U.S. LLC, Whippany, NJ, USA.
FAU - Simmons, Stacey J
AU  - Simmons SJ
AD  - Bayer U.S. LLC, Whippany, NJ, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200729
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Androgen Antagonists)
RN  - 0 (Antineoplastic Agents, Hormonal)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Androgen Antagonists/adverse effects/*therapeutic use
MH  - Antineoplastic Agents, Hormonal/adverse effects/*therapeutic use
MH  - *Caregivers
MH  - *Choice Behavior
MH  - Cross-Sectional Studies
MH  - Female
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Patient Preference
MH  - Patient Safety
MH  - Prostatic Neoplasms, Castration-Resistant/diagnosis/*drug therapy/mortality
MH  - Risk Assessment
MH  - Risk Factors
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
PMC - PMC7520320
OTO - NOTNLM
OT  - Caregivers
OT  - Choice Behavior
OT  - Patients
OT  - Prostatic Neoplasms, Castration-Resistant
OT  - Risk Assessment
COIS- SS consulted for Bayer US LLC and Janssen, and has received research funding from 
      Bayer and Pfizer. AFM and ARW are full-time employees of Bayer US LLC and own 
      stocks in Bayer. SJS is a full-time employee of Bayer US LLC and own stocks in 
      Bayer and Pfizer. SA is a full-time employee of Bayer US LLC. MB is a shareholder 
      of Pharmerit International, the institution which received funding from Bayer, 
      for conducting the study. MB, XN, NJ, JT, and JF are full-time employees of 
      Pharmerit International.
EDAT- 2020/07/30 06:00
MHDA- 2021/07/21 06:00
PMCR- 2020/07/29
CRDT- 2020/07/30 06:00
PHST- 2019/12/18 00:00 [received]
PHST- 2020/06/25 00:00 [revised]
PHST- 2020/06/26 00:00 [accepted]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/07/21 06:00 [medline]
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/29 00:00 [pmc-release]
AID - CAM43321 [pii]
AID - 10.1002/cam4.3321 [doi]
PST - ppublish
SO  - Cancer Med. 2020 Sep;9(18):6586-6596. doi: 10.1002/cam4.3321. Epub 2020 Jul 29.